anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention pertains to a method for decreasing the body fat proportion, increasing lean body mass ("LBM"), increasing bone density, or improving the rate of bone healing, or all, of a subject. Overall, the embodiments of the invention can be accomplished by delivering a heterologous nucleic acid sequence encoding GHRH or functional biological equivalent thereof into the cells of the subject and allowing expression of the encoded gene to occur while the modified cells are within the subject. For instance, when such a nucleic acid sequence is delivered into the specific cells of the subject tissue specific constitutive expression is achieved. Furthermore, external regulation of the GHRH or functional biological equivalent thereof gene can be accomplished by utilizing inducible promoters that are regulated by molecular switch molecules, which are given to the subject. The preferred method to deliver the constitutive or inducible nucleic acid encoding sequences of GHRH or the functional biological equivalents thereof is directly into the cells of the subject by the process of in vivo electroporation. A  decrease the body fat proportion and an increase in lean body mass ("LBM"), or both of a subject is achieved by the delivery of GHRH or functional biological equivalent thereof as described herein by into the subject as recombinant proteins. In addition, an increase in bone density and improvement in the rate of bone healing is also achieved.
Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
Aging and obesity are associated with a decrease in plasma 25-hydroxyvitamin D (25(OH)D) levels. In the context of a growing aging population and the rising incidence of obesity, we hypothesized that aging process, either independently or in combination with obesity, could influence vitamin D (VD) metabolism, consequently resulting in the reduced 25(OH)D plasma concentrations. C57BL/6JRJ young (6 months) and old (23 months) mice fed with control (CD) or high fat diet (HF) were compared. Plasma and adipose concentration of cholecalciferol and 25(OH)D and mRNA expression of genes coding for the main VD actors were analyzed. Aging was associated with a decrease in plasma 25(OH)D levels, whereas combined effect of obesity and aging did not generate a cumulative effect on plasma 25(OH)D levels. The mRNA expression of Cyp27a1, Cyp3a11, and Cyp2j6 were decreased in the liver during aging. Together, these regulations could explain the reduced 25-hydroxylation. Interestingly, the lack of cumulative reduction of 25(OH)D in aged and obese mice could be related to the strong induction of Cyp2j6. In kidneys, a complex modulation of Cyp27b1 and Cyp24a1 could contribute to the reduced 25-hydroxylation in the liver. In white adipose tissue, an induction of Cyp2r1 was observed during aging and obesity, together with an increase of 25(OH)D quantity, suggesting an exacerbated storage that may participated to the reduced plasma 25(OH)D levels. These findings support the notion that aging alone or combined with obesity, induces regulation of VD metabolism in the organs, beyond the classical reduction of epidermal VD precursor, which may contribute to the decrease in 25(OH)D levels.
Aim 2: Participants will perform learning tasks combined with shifted auditory feedback. Motor cortical excitability will be measured using single-pulse TMS to elicit motor evoked potentials.
The juice obtd by pressing or centrifuging cocoa fruits is useful as a binder for foodstuffs e.g. sherbets, ice-cream, fruit drinks, dairy produce etc. Alternatively the juice may be treated to ppt. those component which make it viscous and the ppt. dried and powdered and using in place of the juice itself. Pref. juice is 0.1-20% on completed product.
PURPOSE:To provide the titled health-promoting agent prepared by mixing ground tea with wheat embryo oil, thereby dissolving the chlorophyll-a caffeine of te chlorophyll contained in the ground tea, in the wheat embryo oil. CONSTITUTION:The health-promoting agent can be prepared by mixing 100pts. wt. of ground tea with 30-150pts.wt. of wheat embryo oil, thereby dissolving chlorophyll-a and caffeine of chlorophyll contained in the ground tea in wheat embryo oil. Ground tea contains, as principal components, 10-25wt% of chlorophyll (chlorophyll-a accounts for 0.001-0.005wt% thereof), 30-50wt% of proteins and 0.3-1.6wt% of caffeine; and wheat embryo contains 10-20wt% of proteins, 20-30wt% of lipid and 0.5-1.0wt% of vitamin E. The components existing in the above components can be transferred effectively to the tissue in the body by mixing both components at a proper ratio. The chlorophyll-a and caffeine take stable form when dissolved in wheat embryo oil.
HPIV type 3 (HPIV3) ranks second only to respiratory syncytial virus as the most important cause of bronchiolitis and pneumonia in infants less than 6 months of age. HPIV3 can cause severe disease in the first 2 years of life and is responsible for 11% of hospitalizations for respiratory diseases in children. This study will evaluate the safety and immunogenicity of a live recombinant attenuated intranasal HPIV3 vaccine, rHPIV3cp45.

This study will last for a maximum of 180 days. Infants will be enrolled into one of two study groups, Group 1 or Group 2. Depending on the study location, groups will enroll either sequentially or concurrently. Within each group, infants will be randomly assigned to receive 2 immunizations of rHPIV3cp45 or placebo. Immunizations will be given as nose drops. Immunizations will be given at study entry and approximately 4 to 10 weeks after study entry.

On the day of immunization, a physical exam, vital signs measurement, blood collection, and medical history will occur. Infants will be observed for 15 minutes after immunization for any immediate adverse effects. Parents or guardians will be given a thermometer to take with them and will be instructed on how to take their infant's temperature. They will be given the study schedule and will need to provide contact phone numbers so study personnel can contact them by phone during the days after immunization. Parents and guardians will be contacted by telephone on days without study visits, from Day 1 to Day 19 and on Day 180 after immunization, and asked about any illnesses or adverse effects they have observed in their immunized infants.

Parents or guardians will need to record their infant's temperature daily for at least the 17 days immediately following immunization. During this 17-day period, there will be at least 6 study visits associated with each immunization; visits will occur on the day of immunization and approximately 3, 7, 10, 14, and 17 days after immunization. At all study visits, infants will undergo a physical exam and vital signs measurement. Group 1 participants will also undergo a nasal wash for a viral culture. There will be additional follow-up visits occurring sometime between 28 and 70 days after the first dose and 28 to 35 days after the second dose; blood collection will occur at the follow-up visits. Additional visits may be required on selected days during the month after immunization. Infants who experience illness or side effects may be asked to return to the clinic for examination. Parents or guardians will be made aware of whether their infant received the HPIV vaccine or placebo 18 days after the second immunization or in the event of a lower respiratory tract illness.
The present invention relates to inducible viral replicons as regulatable live-attenuated vaccine candidates. In particular, it relates to the HIV-rtTA replicon whereby, aiming for regulated expression of the replicon, the rtTA gene has been inserted into the HIV1-Nef gene (i.e. under control of Nef regulatory elements), the TetO elements have been inserted into one or either LTRs, and the NF-Kappa-B sites of said LTRs have of have not been mutated. Aiming for further attenuation, the TAR hairpin and eventually also the Tat gene have been mutated. A conditional cytotoxic gene (e.g. HSV-tk) can eventually also be inserted into the replicon to provide for improved biosafety. Said replicon is intended to be used as live-attenuated HIV1 vaccine, but forced evolution (i.e. genetic drift of HIV due to the relatively poor fidelity of HIV1 RT) could be used to improve the present mutants, as well as to select for modified/improved rtTA-TetO regulatory systems.  <IMAGE>
Infections are widespread in Pediatric and Neonatal ICU, and antibiotic treatments widely used. Long courses of antibiotic treatment increase the duration of hospitalization and are associated with changes in the microbiome, emergence of multidrug resistant organisms, and antibiotic-associated adverse events. In Pediatric and Neonatal ICU, PCT has a high negative predictive value to rule out bacterial infection. Thus, in sepsis patients and patients who initially appear to have sepsis but whose final diagnosis of bacterial infection is not retained, the use of a PCT-guided algorithm may be of value to shorten antibiotic duration without increasing infection recurrences. The algorithm has provided strong evidence of efficacy and safety among critically ill adults, excluding immunocompromised patients, patients with cystic fibrosis, and infections requiring prolonged antibiotic therapy. Similar data in critically ill children are lacking. A Spanish team from Sant Joan de Déu published three prospective non-randomized studies in Pediatric ICU (PICU), with encouraging results. Only one American randomized controlled trial (RCT) has been published in PICU with mixed results. One RCT is ongoing in India. Thus, our study will be the first French RCT to study the use of a PCT-guided algorithm to de-escalate antibiotic therapy in PICU, in order to provide evidence of efficacy and safety of such an algorithm in critically ill children with a suspected or proven bacterial infection. In addition, investigator team will also study the economic impact of a PCT-guided algorithm which has never been done before.

In the PCT-guided arm, PCT dosage will be done at Day 0 (day of randomization) and Day 1, and then every 48 hours until cessation of antibiotics in hospital or discharge from hospital if the patient is discharged with an antibiotic treatment. Antibiotic treatment will be stopped according to PCT value and patient clinical evolution. In the control group, antibiotic duration will be determined by usual practices based on guidelines. Inpatient evaluations will be conducted every day so long as patients receives antibiotics in hospital and usual clinical, biological and/or radiological monitoring will be conducted in both groups. To monitor infection recurrence occurring up to 28 days after the day of randomization and antibiotic-related adverse events, an evaluation will be conducted at the end of hospitalization, another at Day 28 (Day 0 = day of randomization), and a last at the end of antibiotic treatment bacterial infection recurrence, if the patient is discharged from hospital on or before Day 28 and is still treated with antibiotics for a bacterial infection recurrence at Day 28, or if the patient is discharged from hospital after Day 28 and is still treated for recurrence on the last day of hospitalization with antibiotics for a bacterial infection recurrence.
The present invention provides compositions suitable for use as biomarkers of vulnerable plaques as well as methods for the use of such compositions. In preferred embodiments, specific molecular imaging agents are provided that permit the selective identification of vulnerable plaques in coronary and other arteries using non- invasive imaging methods. Such specific molecular imaging agents comprise a binding partner linked to a detectable label that can be used in vivo to visualize vulnerable plaques. In certain preferred embodiments, the binding partner is a peptide that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is an antibody that binds selectively to a component of a vulnerable plaque. In other preferred embodiments, the binding partner is a portion of a polypeptide displayed by a bacteriophage that binds selectively to a component of a vulnerable plaque. In preferred embodiments, the component of a vulnerable plaque is myeloperoxidase or a portion thereof.
To provide methods for in vivo delivery of oligonucleotides.SOLUTION: The invention utilizes the presence of one or more HES linked to an oligonucleotide to deliver a nucleic acid sequence of interest to the cytoplasm of a cell and a tissue of an organism. The delivery vehicle is not toxic to cells and organisms. Since the delivery is sequence-independent, and the oligonucleotide to be delivered crosses membranes in a receptor-independent manner, the delivered oligonucleotide can target a complementary sequence in the cytoplasm and nucleus of a living cell. A sequence derived from a bacterium or virus can also be targeted. This method can be used for delivery of a gene encoding the expression of a specific protein, an antisense oligonucleotide, siRNA, shRNA, Dicer substrate, miRNA, anti-miRNA or any nucleic acid sequence in a living organism. The living organism includes mammals, plants, and microorganisms such as bacteria, protozoa and virus.SELECTED DRAWING: Figure 1b
PURPOSE:A cosmetic, prepared by finely dividing dimethylpolysiloxane with a specific hydrocarbon and/or an ester as a finely dividing agent, having improved stability, capable of exhibiting improved properties, e.g. lubricity, and suitable for the hair, skin, etc. CONSTITUTION:An emulsified cosmetic, containing dimethylpolysiloxane, and prepared by finely dividing the dimethylpolysiloxane with a finely dividing agent consisting of one or more hydrocarbons and/or esters positioned in a region at 0-30 deg.(theta) in the formula tantheta=(values of inorganic nature/values of organic nature) in an organic conceptional diagram obtained by plotting the values of the organic nature as the abscissa, and the values of the inorganic nature as the ordinate, i.e. isopropyl myristate, iropropyl palmitate, liquid paraffin or squalane, which are liquid at ordinary temperature and one or more mono- or diesters of a polyol, e.g. neopentyl glycol-2-ethylhaxanate or ethylene glycol monostearate.
Lewy body dementia (LBD) is the second most frequent neurodegenerative disorder after Alzheimer disease (AD). In this study, we compared functional decline between LBD and AD patients, considering motor dysfunction, over an 18-month follow-up period. We included all patients >70 years of age, with initial MMSE ≥ 20 and a diagnosis of possible or probable LBD or AD, who consulted at the memory centre of the Pitié-Salpêtrière hospital. Statistical analyses were performed using univariate tests and multivariate linear regression. Thirty-seven AD and 36 LBD patients were included, with a median age of 81 and a median MMSE score of 24/30. Global ADL Katz score decreased significantly for LBD people, compared to AD patients: -0.40 ± 0.75 versus 0 ± 0.24; p=0.003. Global IADL score decreased in the two populations but without a significant difference between the two groups: -1.71 ± 2.19 in LBD versus -1.32 (± 1.55); p=0.38. This study shows a significant decrease in autonomy in LBD patients over time that was faster than that in AD patients, related, in particular, to bathing, dressing and personal care.
A bamboo liquid honey is a multiusage drug made by mixing tabasheer, agaric, weeping forsythia, cape jasmine, acanthopanax or ginseng, senna leaf, astragalus root, honey. The preparing processes are as following; astragalus root, acanthopanax or ginseng is crushed, boiled filtered, concentrated, honey added. Senna leaf and tabasheer cooker by gentle fire respectively are added into the above concentrated liquid. Mixing evenly, disinfecting, and sterilizing above mixture to produce the finished product. The invented drug is provided with advantages of appropriate taste, convenient for being taken orally or keeping in mouth, as external drug used to treat skin disease. The bamboo liquid honey can apply to multi diseases such as disease of the respiratory system, department of gynecology, urinary system, sternal rib and soft tissue injury, hypersensitive agria on skin with reliable curative effect. It also is provided with effects of regulating qi and relieving flatulence, tonifying the kidney and soothing the nerves, reducing weight and protecting and strengthening health, enhancing immunity.
Participants with hepatocellular carcinoma (HCC) will receive E7386, once daily (QD) for 5 or 6 consecutive days followed by a period of time without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386, QD in combination with lenvatinib 8 milligram (mg) (participants with body weight of less than \[\<\] 60 kilograms \[kg\]) or 12 mg (participants with body weight \>=60 kg), capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
Echinococcosis is a zoonotic disease caused by parasites belonging to the genus Echinococcus that primarily affect the liver. The western plateau and pastoral areas of China are high-risk regions for hepatic cystic echinococcosis and hepatic alveolar echinococcosis (HAE). The high late mortality rate associated with HAE underscores the critical need for early diagnosis to improve cure rates and mitigate the disease burden in endemic areas. Currently, the World Health Organization recommends ultrasonography as the preferred initial screening method for hepatic echinococcosis. However, distinguishing between specific types of lesions, such as those of hepatic cystic echinococcosis and HAE, and other focal liver lesions is challenging. To address this issue, contrast-enhanced ultrasound is recommended as a tool to differentiate solid and cysto-solid hepatic echinococcosis from other focal liver lesions, significantly enhancing diagnostic accuracy. In this comprehensive review, we discuss the progression of hepatic echinococcosis and detail the imaging features of various types of echinococcosis using conventional, contrast-enhanced, and intraoperative ultrasound techniques. Our objective is to provide robust imaging evidence and guidance for early diagnosis, clinical decision making, and postoperative follow-up in regions with high disease prevalence.
A method and a system for generating a strain map of a dissected blood vessel. A multiphase stack of the dissected blood vessel is received, with a given phase of the multiphase stack representing the blood vessel at a given time in a cardiac cycle. A 3D geometrical model of the blood vessel includes a wall of the blood vessel and a dissection flap is generated. A surface mesh of the blood vessel for a first phase is generated, the surface mesh including a blood vessel wall surface mesh and a dissection flap surface mesh. A local deformation at each phase is determined by mapping voxels of the surface mesh of the blood vessel to the multiphase stack. A strain map including principal strain values is generated using the local deformation and the blood vessel wall surface mesh and the dissection flap surface mesh.
Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
284 student athletes will be enrolled in this two-arm quasi-experimental study. The participants will be boys and girls, aged 13 to 16 years who compete in any sport. Participants will be recruited and enrolled through partnerships with their school physical education and/or sport programs. Participants will complete baseline questionnaires assessing demographics, history of sport participation, and psychological variables related to doping prevention including knowledge, doping self-regulatory efficacy, motivation, attitudes, intentions, perceived norms, doping refusal, substance use behaviours, and doping related protective behaviours (e.g., checking the list of ingredients on medications). Participants will then be assigned to either an intervention group (n = 142; the doping videogame the investigators are developing) or a comparison group (n = 142). The comparison group will be given printed educational materials about doping education, developed by an accredited source (e.g., UNESCO). Assignment to the intervention or comparison group will be conducted at the level of the school to reduce the potential for contamination that could occur if intervention and comparison students were interacting in their school environment and sharing information they learned from the game. Participants from the intervention group will play five, 60-minute sessions over the course of one month (5 hours of total gameplay). Before the gameplay sessions begin, the Project Director and research assistants will orient the intervention group participants to the use of the intervention videogame. Players will be given a tutorial on an iPad demonstrating the mechanics of the game and how to use the iPad. Each player will have their own dedicated iPad that they will use during each game play session (this will be provided by the research team). Shortly after the last gameplay session is completed, participants from both groups will be asked to complete a questionnaire assessing the same psychological variables assessed at baseline as well as their gameplay experience. The psychological variables will also be assessed at three, six, and 12 month follow-ups.
FIELD: medical industry. SUBSTANCE: method comprises filtering original solution of water soluble aluminium salt and sodium phosphate on microfiltration plant with threshold of passage of 0.22 mcm, reacting water soluble aluminium salt with sodium phosphate, precipitating the desired product under vigorous stirring for 15-45 min at agitator rotational rate of 3.3-3.8 s -1  at 18-60 C for 5- 7 days, forming aluminium phosphate gel and subsequently washing it. Reaction is carried out by addition of sodium phosphate solution to aqueous solution of aluminium salt. Aluminium phosphate gel is separated from supernatant liquid by decantation which is carried out at temperatures from 7 to 18 C. Invention makes it possible to prepare standard aluminium phosphate gel used as substrate for producing antacidal and vaccine drugs. EFFECT: more efficient preparation method. 4 cl